Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
- About
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: DMAA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $0
1 Year Target Price $0
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 9.95 - 10.27 | Updated Date 05/1/2025 |
52 Weeks Range 9.95 - 10.27 | Updated Date 05/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Drugs Made In America Acquisition Corp. Ordinary Shares
Company Overview
History and Background
Drugs Made In America Acquisition Corp. (DMAQ) is a blank check company (SPAC) formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It was founded in 2020.
Core Business Areas
- Special Purpose Acquisition Company (SPAC): DMAQ's sole purpose is to identify and merge with a private company, effectively taking that company public. It has no operational business until an acquisition is completed.
Leadership and Structure
The leadership team consists of individuals with experience in finance and the pharmaceutical industry. The organizational structure is typical of a SPAC, with a board of directors and a management team focused on deal sourcing and execution.
Top Products and Market Share
Key Offerings
- Initial Public Offering (IPO) Units: DMAQ offered units to investors in its IPO. These units represent a combination of shares of common stock and warrants to purchase additional shares. The value of these units is tied to the success of the future acquisition. Competitors include other SPACs pursuing mergers.
Market Dynamics
Industry Overview
The SPAC market is volatile and cyclical, influenced by investor sentiment and macroeconomic conditions. Increased regulatory scrutiny and a flood of SPACs seeking targets have increased competition and deal complexity.
Positioning
DMAQ is positioned as a SPAC seeking to acquire a company in the healthcare or pharmaceutical sector. Its competitive advantage depends on its management team's deal-sourcing abilities and its ability to offer attractive terms to potential target companies.
Total Addressable Market (TAM)
The TAM is difficult to quantify as it depends on the specific sector DMAQ is targeting within healthcare/pharmaceuticals. DMAQ's position within the TAM is determined by its ability to secure a high-quality acquisition target.
Upturn SWOT Analysis
Strengths
- Experienced management team
- Access to capital through IPO
- Flexibility to pursue various acquisition targets
Weaknesses
- Limited operating history
- Reliance on finding a suitable acquisition target
- Time constraint to complete an acquisition
Opportunities
- Potential to acquire a high-growth company
- Favorable market conditions for healthcare/pharmaceutical companies
- Increased investor interest in innovative healthcare technologies
Threats
- Increased competition from other SPACs
- Unfavorable market conditions impacting acquisition valuations
- Regulatory changes affecting the healthcare/pharmaceutical industry
- Failure to find a suitable acquisition target
Competitors and Market Share
Key Competitors
- Other SPACs (no specific US ticker symbols)
Competitive Landscape
The competitive landscape is highly fragmented, with numerous SPACs seeking acquisition targets in various sectors. DMAQ's success depends on its ability to differentiate itself and offer a compelling deal to potential targets.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is not applicable as a SPAC prior to acquisition.
Future Projections: Future growth is entirely dependent on the acquisition target and its future performance.
Recent Initiatives: Recent initiatives are focused on identifying and evaluating potential acquisition targets.
Summary
Drugs Made In America Acquisition Corp. is a SPAC without current operations that faces uncertainties related to securing a merger. Its performance hinges on finding a suitable acquisition target. The high level of competition within the SPAC market poses a risk to the company's success. The companyu2019s success depends on its ability to differentiate itself and offer a compelling deal to potential targets. If it cannot find a suitable merger partner within the allotted time, its initial funding will be given back to the investors.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Financial News Outlets
Disclaimers:
This analysis is based on publicly available information and is not financial advice. SPAC investments are speculative and involve significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Drugs Made In America Acquisition Corp. Ordinary Shares
Exchange NASDAQ | Headquaters Fort Lauderdale, FL, United States | ||
IPO Launch date 2025-02-25 | CEO & Executive Chairman Ms. Lynn Stockwell | ||
Sector Financial Services | Industry Shell Companies | Full time employees - | Website https://dmaacorp.com |
Full time employees - | Website https://dmaacorp.com | ||
Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in Fort Lauderdale, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.